Please assess the completion status of the following clinical trial:

Trial Title: IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female between 18 and 70 years old;~* Patients with histologic proved metastatic breast cancer;~* Pleural effusion with the volume of more than 1000ml, as documented by CT, X ray or ultrasound;~* There are no other diseases which cause the elevation of IL-6 or IL-8, such as cirrhosis of liver, anaphylactoid purpura, acute pancreatitis;~* With at least one measurable disease according to RECIST criteria,~* Normal laboratory results:ANC≥2.0×109/L,Hb≥80g/L,plt≥100×109/L,TB\<UNL (\<1.5 x UNL in patients with liver mets),ALT/AST\< 1.5 x UNL (\<2.5x UNL in patients with liver mets),AKP\<5 x UNL(except bone mets),Cr\<UNL;~* Normal functions with heart, liver,renal and bone marrow;~* Got ICF before enrollment;~* Life expectancy more than 12 weeks.~Exclusion Criteria:~* Pregnant or breast-feeding women or positive serum pregnancy test;~* Uncontrolled brain metastases;~* No recovery from previous radiation or accepted radiation within 4 weeks before enrollment;~* Participation in any investigational drug study within 4 weeks preceding treatment start;~* Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin;~* Serious uncontrolled intercurrent infections;~* Poor compliance.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- pleural effusion (Type: None): patients with pleural effusion

Based on this trial design, predict the completion outcome and termination type (if applicable).